Sign In
Buy XLRN
$178.75
+0 (+0%)
At Close: May 27, 2022
Avoro Capital Advisors LLC Buys Acceleron Pharma Inc, Apellis Pharmaceuticals Inc, Aadi ...
06:38pm, Monday, 15'th Nov 2021 GuruFocus
Related Stocks: XLRN , APLS , FOLD , PMVP , RNA , AADI , KYMR , DICE , BIIB , NUVL , TNGX , CNST , RLMD , OLMA , CNTA , BCTG , ADAP ,
Is Merck's Planned Acquisition of Acceleron in Trouble?
07:31am, Friday, 12'th Nov 2021
There's nothing to worry about with a recent delay.
Avoro Capital Releases Presentation Detailing Why Acceleron Shareholders Should Not Tender Into Merck's Inadequate Offer
05:31pm, Tuesday, 09'th Nov 2021
NEW YORK--(BUSINESS WIRE)--Avoro Capital Advisors (“Avoro”), a long-term and collaborative investor in life sciences and biotechnology companies, together with certain of its affiliates and manage
Acceleron Pharma (XLRN) Reports Q3 Loss, Lags Revenue Estimates
07:04pm, Thursday, 04'th Nov 2021
Acceleron (XLRN) delivered earnings and revenue surprises of 1.04% and -6.62%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Acceleron Reports Third Quarter 2021 Financial Results
04:01pm, Thursday, 04'th Nov 2021
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq:XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics
SHAREHOLDER ALERT: WeissLaw LLP Reminds DWSN, PAE, XLRN, and FLXN Shareholders About Its Ongoing Investigations
09:25pm, Monday, 01'st Nov 2021
NEW YORK, Nov. 1, 2021 /PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights o
Merck Pushes Acceleron Buyout By Refiling For Antitrust Review
05:10pm, Monday, 01'st Nov 2021
Merck & Co Inc (NYSE: MRK) revealed that it had temporarily withdrawn its premerger notification and report form. The company said it plans to refile today.
Avoro Capital Issues Open Letter to Fellow Acceleron Pharma Shareholders
08:00am, Thursday, 28'th Oct 2021
NEW YORK--(BUSINESS WIRE)--Avoro Capital Advisors (“Avoro”), a long-term and collaborative investor in life sciences and biotechnology companies, beneficially owns approximately 7% of Acceleron Ph
Acceleron Announces Third Quarter 2021 REBLOZYL® Net Sales
07:10am, Wednesday, 27'th Oct 2021
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq:XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics
SHAREHOLDER ALERT: WeissLaw LLP Reminds MDP, GWB, XLRN and HFC Shareholders About Its Ongoing Investigations
06:30pm, Friday, 22'nd Oct 2021
NEW YORK, Oct. 22, 2021 /PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights
Bristol Myers Pledges To Offload Acceleron Shares: Bloomberg
01:10pm, Thursday, 21'st Oct 2021
Bristol-Myers Squibb Co (NYSE: BMY) is planning to tender its shares in Acceleron Pharma Inc (NASDAQ: XLRN) after Merck & Co Inc (NYSE: MRK) agreed to buy the biotechnology company for $11.5 bill
Darwin Global Urges Acceleron Shareholders Not to Tender Their Shares to Merck
08:00am, Wednesday, 20'th Oct 2021
JERSEY, Channel Islands--(BUSINESS WIRE)--Darwin Global Management Limited (“Darwin Global”), a long-term investor in the biotechnology and pharmaceutical sector and beneficial owner of 2,345,620
ACCELERON PHARMA ALERT: Investors Should Contact Bragar Eagel & Squire, P.C. Over Tender Offer for XLRN Shares
11:54am, Monday, 18'th Oct 2021
NEW YORK--(BUSINESS WIRE)-- #Acceleron--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the officers or directors of Accele
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Acceleron Pharma Inc. - XLRN
05:56pm, Wednesday, 13'th Oct 2021
NEW YORK, Oct. 13, 2021 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018-2020 ISS Securities Class Ac
Holocene Advisors says Merck's offer undervalues Acceleron
04:09pm, Wednesday, 13'th Oct 2021
Investment management firm Holocene Advisors said it will not tender its shares in Acceleron Pharma Inc into Merck & Co's proposed $180 per share offer for the drugmaker, as it significantly undervalu
